ArticleBMC microbiology2026
Effects of lipid-lowering drug on vancomycin-sensitive Corynebacterium kroppenstedtii.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundGranulomatous mastitis (GM) is a rare inflammatory breast disease primarily affecting reproductive-aged women with a history of breastfeeding. Within GM lesions, Corynebacterium kroppenstedtii has frequently been isolated, suggesting it may play a significant role in the development of GM. It is important to develop the novel therapeutic regimen to fight against the Corynebacterium kroppenstedtii infection.
resultsIn our study, the combination of vancomycin and the lipid-lowering drug Tetrahydrolipstatin (THL) exhibited a synergistic effect against bacteria. Proteomic analysis revealed that potential targets of THL are involved in intermediary metabolism, cellular respiration, lipid metabolism, signaling pathways, virulence, and detoxification and adaptation processes.
conclusionsThe combination of THL and vancomycin could be a novel therapeutic regimen to enhance clinical outcomes and reduce the recurrence of GM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.